I B Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.74 M
as on 16-11-2024
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.33 Cr
as on 16-11-2024
- Satisfied Charges ₹ 12.87 Cr
as on 16-11-2024
- Revenue 5.22%
(FY 2023)
- Profit 60.50%
(FY 2023)
- Ebitda 37.20%
(FY 2023)
- Net Worth 20.02%
(FY 2023)
- Total Assets 5.24%
(FY 2023)
About I B Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.74 M.
The company currently has active open charges totaling ₹16.33 Cr. The company has closed loans amounting to ₹12.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manoj Goyal and Ritu Goyal serve as directors at the Company.
- CIN/LLPIN
U51397DL2007PTC166799
- Company No.
166799
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does I B Pharma Private Limited offer?
I B Pharma Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Injectable Products, Botox Injection, Goserelin Acetate Injection, Antiviral Drugs, Sofosbuvir Tablets, Cardiovascular Drugs & Medication, Immunosuppressive Drugs, Darzalex Injection.
Who are the key members and board of directors at I B Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Goyal  | Director | 13-Aug-2020 | Current |
| Ritu Goyal | Director | 13-Aug-2020 | Current |
Financial Performance of I B Pharma.
I B Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.22% increase. The company also saw a substantial improvement in profitability, with a 60.5% increase in profit. The company's net worth Soared by an impressive increase of 20.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I B Pharma?
In 2023, I B Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 May 2024 | ₹8.60 Cr | Open |
Hdfc Bank Limited Creation Date: 24 Aug 2021 | ₹2.43 M | Open |
Yes Bank Limited Creation Date: 27 Jun 2015 | ₹7.49 Cr | Open |
How Many Employees Work at I B Pharma?
I B Pharma has a workforce of 5 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I B Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I B Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
